Every value below carries the sentence it was read from.
96 sources stand behind the page.
Field
Value
Cited text
Known as
buparlisib
“Buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus fulvestrant in the BELLE-2 study significantly improved progression-free survival (PFS) in patients with...” PMID 30241001 ↗Sep 201828
“PURPOSE: Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K...” PMID 30715997 ↗Feb 2019
“This study evaluated the combination of buparlisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, with imatinib in patients with advanced GIST, who have failed prior...” PMID 32147671 ↗Mar 2020
“A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified...” PMID 28281183 ↗Mar 2017
“Mouse-human co-clinical trials demonstrate superior anti-tumour effects of
buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head
and neck.” PMID 32963347 ↗Sep 2020
“PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.” PMID 28950146 ↗Sep 2017
“Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.” PMID 33138866 ↗Nov 2020
“Buparlisib (BKM120) is the investigational drug.” NCT01132664 ↗
“ribociclib plus buparlisib plus fulvestrant” PMID 32887722 ↗Sep 2020
ChEMBL registry synonym — accepted as the source's own labelCHEMBL2017974 ↗
Known as
BKM-120NX
ChEMBL registry synonym — accepted as the source's own labelCHEMBL2017974 ↗
Known as
BKM120
“Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week...” NCT01911325 ↗71
“BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.” NCT01300962 ↗
“The purpose of this study is to find out what effects, good and/or bad, Buparlisib (also known as BKM120) has on lymphoma and the central nervous system.” NCT02301364 ↗
“A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors” NCT01576666 ↗
“BKM-120 is a pan-PI3K inhibitor currently tested in clinical trials.” NCT01806649 ↗
“Buparlisib (BKM120) is the investigational drug.” NCT01132664 ↗
ChEMBL registry synonym — accepted as the source's own labelCHEMBL2017974 ↗
Known as
NVP-BKM120
“NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.” NCT01550380 ↗
Action
Inhibit
“clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor.” NCT01068483 ↗